ANI Pharmaceuticals Inc. (NASDAQ:ANIP) shares dropped 2.1% on Thursday . The company traded as low as $63.34 and last traded at $63.36, with a volume of 136,460 shares trading hands. The stock had previously closed at $64.71.

ANIP has been the subject of a number of research reports. Guggenheim reissued a “buy” rating and set a $80.00 target price (up from $65.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 5th. Citigroup Inc. raised shares of ANI Pharmaceuticals to an “outperform” rating and set a $65.00 target price for the company in a research report on Tuesday, July 19th. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $67.00 target price for the company in a research report on Wednesday, July 20th. Standpoint Research downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 24th. Finally, Raymond James Financial Inc. initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, June 22nd. They set a “strong-buy” rating and a $68.00 target price for the company. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $64.00.

The stock has a market cap of $727.34 million and a price-to-earnings ratio of 74.23. The stock has a 50 day moving average of $62.52 and a 200-day moving average of $48.38.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.34. The firm earned $31.30 million during the quarter, compared to analysts’ expectations of $27.63 million. The firm’s quarterly revenue was up 60.5% on a year-over-year basis. During the same period last year, the firm posted $0.55 earnings per share. On average, equities analysts anticipate that ANI Pharmaceuticals Inc. will post $4.12 earnings per share for the current fiscal year.

In other ANI Pharmaceuticals news, insider Arthur Przybyl sold 37,455 shares of ANI Pharmaceuticals stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $66.97, for a total value of $2,508,361.35. Following the completion of the transaction, the insider now directly owns 200,788 shares of the company’s stock, valued at $13,446,772.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Robert W. Schrepfer sold 12,500 shares of ANI Pharmaceuticals stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $67.06, for a total transaction of $838,250.00. Following the completion of the transaction, the vice president now directly owns 17,362 shares of the company’s stock, valued at $1,164,295.72. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in ANI Pharmaceuticals stock. Schwab Charles Investment Management Inc. raised its stake in shares of ANI Pharmaceuticals Inc. (NASDAQ:ANIP) by 16.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,681 shares of the specialty pharmaceutical company’s stock after buying an additional 3,400 shares during the period. Schwab Charles Investment Management Inc. owned about 0.21% of ANI Pharmaceuticals worth $1,069,000 at the end of the most recent reporting period.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.